Bactana Corp., a Cornell-licensed biotechnology startup developing postbiotic solutions to improve intestinal and metabolic health, has been acquired by global ingredient manufacturer Kemin Industries. The acquisition positions Bactana to expand the reach of its microbiome-based innovations, particularly in the animal health sector, and brings its research-driven technology closer to global commercialization. With a foundation in Cornell research and support from the UConn Technology Incubation Program, Bactana has made significant strides in isolating beneficial anaerobic bacteria and developing sustainable alternatives to antibiotics in livestock and companion animals.
This acquisition marks a major milestone in Bactana’s journey from lab to market, highlighting the value of academic innovation and early-stage incubation in driving breakthrough technologies. With Kemin’s global footprint and manufacturing expertise, Bactana is now poised to scale its impact and contribute to a healthier, more sustainable future for animals — and potentially humans — worldwide.
“We are incredibly grateful to our employees, advisors, and shareholders for their continued support and confidence in our vision over the past six years,” said John Kallassy, CEO of Bactana Corp. “This agreement, coupled with Kemin’s global reach, will help us better position our technology for global application—particularly in the animal health sector—and improve the well-being of animals, and potentially people, around the world for years to come.”
